Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones

Inhibrx Inc (ISIN: US45720L1070) released fourth quarter and full-year 2025 financial results on March 19, 2026, revealing cost cuts, fresh debt funding, and upcoming data readouts for its oncology candidates. The Nasdaq-listed biotech now eyes BLA submission and trial updates that could reshape its trajectory.

Inhibrx Inc stock jumped after the company unveiled its fourth quarter and fiscal year 2025 financial results on March 19, 2026. The Nasdaq-listed biotech reported a net loss of $140.1 million for the year, but slashed R&D expenses to $113.0 million from $203.7 million in 2024 and G&A costs to $23.3 million from $127.9 million. Cash stood at $124.2 million as of December 31, 2025, bolstered by $75.0 million in loan proceeds from Oxford Finance on March 18, 2026. Investors reacted positively to the pipeline focus on ozekibart and INBRX-106, with key readouts slated for 2026.

As of: 20.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Tracking clinical-stage oncology innovators like Inhibrx as they navigate funding crunches and pivotal trial data in a high-stakes therapeutic race.

Core Financial Snapshot from Latest Earnings

Inhibrx Biosciences Inc, trading as INBX on Nasdaq, posted zero revenue in Q4 2025, down from $100,000 the prior year. Full-year revenue scraped to $1.4 million over the trailing twelve months, underscoring its pre-commercial status. The EPS came in at -$2.11 for the quarter, missing estimates of -$2.08 by a slim margin. Despite the losses, operational efficiencies shone through with sharp cost reductions post the divestiture of INBRX-101.

Cash reserves provide a runway into late 2026, assuming steady burn rates. The recent loan amendment extends financial flexibility amid clinical pushes. Debt-to-equity sits at 2.9, paired with a current ratio of 4.49, signaling liquidity strength but leverage risks. Analysts note a hold rating, with RSI nearing oversold at 39.82.

For DACH investors, this setup highlights a classic biotech bet: high burn tolerated for potential blockbuster approvals. German-speaking markets favor such profiles when European trial data looms, like the ESMO 2026 presentation.

Pipeline Pivot to Ozekibart and INBRX-106

Post the INBRX-101 sale and spin-off, Inhibrx streamlined to two assets: ozekibart (INBRX-109) for oncology and INBRX-106, a tumor-targeted immune agonist. Ozekibart targets unresectable or metastatic conventional chondrosarcoma, with a Biologics License Application (BLA) planned for early Q2 2026. This rare sarcoma focus positions it for accelerated approval pathways.

INBRX-106 advances in head and neck squamous cell carcinoma (HNSCC), combined with Merck's Keytruda (pembrolizumab). Interim objective response rate (ORR) data from the Phase 2/3 trial hits in Q2 2026, followed by progression-free survival (PFS) results at ESMO Congress in Q4 2026. These milestones could validate the platform's multivalent protein engineering.

Success here matters for DACH portfolios heavy in healthcare. Switzerland's Roche and Germany's BioNTech set benchmarks in immuno-oncology; Inhibrx's conditional agonists offer a differentiated angle on tumor-selective activation.

Why the Market Reacted Strongly Yesterday

On Nasdaq, Inhibrx Inc stock traded in a range of $62.67 to $68.18 on March 19, 2026, closing around $68.69, up notably from prior levels. The 9.6% gain reflected optimism over cost discipline and catalyst-rich 2026. Historical earnings moves average +3.1%, but this release amplified on pipeline clarity.

Biotech peers often spike on BLA timelines and Phase 3 interim data promises. Inhibrx's debt raise neutralized dilution fears, unlike equity-heavy financings. Market cap hovers near $943 million, with P/S at 720x signaling premium for execution risk.

DACH traders on platforms like Xetra may spot arbitrage, though primary liquidity stays on Nasdaq in USD. The ESMO tie-in adds European flavor, drawing funds from Zurich and Frankfurt.

Investor Relevance for DACH Portfolios

German, Austrian, and Swiss investors should monitor Inhibrx for its alignment with Europe's oncology push. The EMA could fast-track ozekibart if FDA nods, given chondrosarcoma's orphan status. INBRX-106's HNSCC data at ESMO positions it for continental scrutiny.

DACH biotech exposure via ETFs often misses pure-plays like this. With 88% institutional ownership, momentum could build if Q2 catalysts deliver. Currency-hedged USD plays suit conservative mandates amid ECB rate paths.

Risk-adjusted, it complements diversified holdings in Merck KGaA or Lonza, offering upside from protein therapeutics innovation.

Technical and Valuation Context

INBX approaches oversold per RSI-14 at 39.82, with SMA-20 at $73.82 suggesting rebound potential on Nasdaq in USD terms. P/B of 25.54 reflects asset-light biotech norms, but Altman Z-Score of 0.45 flags distress risk if trials falter.

Hold consensus prevails, minimal insider stake at 0.14% underscores execution over alignment. Volume spikes post-earnings signal conviction building.

For mobile traders in DACH, real-time Nasdaq feeds via apps like Trade Republic capture intraday moves without FX headaches.

Key Risks and Open Questions Ahead

Biotech volatility looms large: Q2 ORR data could disappoint if response rates lag Keytruda combos. BLA for ozekibart faces FDA scrutiny on single-arm efficacy. Debt service on $175 million total post-amendment pressures cash if milestones slip.

Net margin at -11,077% screams unprofitability; revenue ramp needs partnerships. Competition in HNSCC from bispecifics and ADCs intensifies. Regulatory delays, common in oncology, could erode runway.

DACH investors weigh this against safe-haven bonds; position sizing caps at 1-2% for high-conviction plays.

Strategic Outlook and Watchpoints

Inhibrx's modular platform promises beyond-core applications, but 2026 defines survival. Positive PFS at ESMO could spark buyouts from Big Pharma eyeing Keytruda synergies. Cost trajectory must hold as trials wrap.

For German-speaking investors, track EMA parallels and potential grants under Horizon Europe for rare cancers. Mobile alerts on Nasdaq INBX/USD set the pulse.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.